Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children

European Journal of Pediatrics

Volumn 171, Issue 3, 2012, Pages 463-470

  Knuf, Markus ^a   Zepp, Fred ^a   Helm, Klaus ^b,c   Maurer, Hartwig ^d   Prieler, Albrecht ^d   Kieninger Baum, Dorothee ^a   Douha, Martine ^e   Willems, Paul ^e  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Pediatric Office   (Germany)

^c Pediatric Office   (Germany)

^d Pediatric Office   (Austria)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

MMRV vaccine; Mumps neutralization; Varicella; Varicella vaccine

Indexed keywords

ANTIBODY; CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; MEASLES MUMPS RUBELLA VACCINE; VARICELLA ZOSTER VACCINE;

ARTICLE; CHICKENPOX; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; IMMUNITY; IMMUNOFLUORESCENCE; IMMUNOGENICITY; INFANT; MEASLES; MULTICENTER STUDY; MUMPS; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SINGLE DRUG DOSE; VACCINATION;

ANTIBODIES, VIRAL; CHICKENPOX; CHICKENPOX VACCINE; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOLLOW-UP STUDIES; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MEASLES; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; MUMPS VIRUS; RUBELLA; RUBELLA VIRUS; VACCINATION; VACCINES, COMBINED;

EID: 84860284348     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-011-1569-4     Document Type: Article

References (41)

1. Advisory Committee on Immunization Practices. June 29-30, 2006. Atlanta, Georgia. Record of the proceedings. http://www.cdc.gov/ vaccines/recs/acip/ meetings.htm#min. Accessed 25 October 2010
2. Arvin A, Gershon A (2006) Control of varicella: why is a twodose schedule necessary? Pediatr Infect Dis J 25:475-476 (Pubitemid 43863354)
3. Australian Government, Department of Health and Ageing, National Health and Medical Research Council (2008) Australian immunisation handbook, 9th edn. National Health and Medical Research Council, Canberra
4. Banz K, Iseli A, Aebi C, Brunner M, Schmutz AM, Heininger U (2009) Economic evaluation of varicella vaccination in Swiss children and adolescents. Hum Vaccin 5:847-857
5. Banz K, Wagenpfeil S, Neiss A, Hammerschmidt T, Wutzler P (2004) The burden of varicella in Germany: potential risks and economic impact. Eur J Health Econ 5:46-53 (Pubitemid 38315897)
6. Boelle PY, Hanslik T (2009) Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 129:599-606
7. Centers for Disease Control and Prevention (2007) Varicella. In: Atkinson W, Hamborsky J, McIntyre L, Wolfe S (eds) Epidemiology and prevention of vaccine-preventable diseases, 10th edn. Public Health Foundation, Washington, pp 175-196
8. Galil K, Lee B, Strine T, Carraher C, Baughman AL, Eaton M, Montero J, Seward J (2002) Outbreak of varicella at a day-care center despite vaccination. N Engl J Med 347:1909-1915 (Pubitemid 35429920)
9. Gil A, San-Martin M, Carrasco P, González A (2004) Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 22:3947-3951 (Pubitemid 39208757)
10. Goh P, Lim FS, Han HH, Willems P (2007) Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection 35:326-333 (Pubitemid 47502355)
11. Grose C (2005) Varicella vaccination of children in the United States: assessment after the first decade 1995-2005. J Clin Virol 33:89-95 (Pubitemid 40725300)
12. Hammerschmidt T, Bisanz H, Wutzler P (2007) Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis. Vaccine 25:7307-7312 (Pubitemid 47484017)
13. Heininger U, Seward JF (2006) Varicella. Lancet 368:1365-1376 (Pubitemid 44540319)
14. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF (2005) Incidence of herpes zoster, before and after varicellavaccination- associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 191:2002-2007 (Pubitemid 40800569)
15. Knuf M, Faber J, Barth I, Habermehl P (2008) A combination vaccine against measles, mumps, rubella and varicella. Drugs Today (Barc) 44:279-292 (Pubitemid 351897261)
16. Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, Descamps D, Willems P (2006) Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella- varicella vaccine in healthy children. Pediatr Infect Dis J 25:12-18 (Pubitemid 43361469)
17. Kreth H, Lee BW, Kosuwon P, Salazar J, Meurice F, Bock H (2008) VarilrixTM: 16 years of experience with the first refrigerator-stable varicella vaccine. BioDrugs 22:387-402
18. Kuter B, Hoffman Brown ML, Hartzel J, Williams WR, EvesiKaren A, Black S, Shinefield H, Reisinger KS, Marchant CD, Sullivan BJ, Thear M, Klopfer S, Xu J, Gress JO, Schödel F, Study Group for ProQuad (2006) Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad®). Hum Vaccin 2:205-214 (Pubitemid 44786802)
19. Kuter B, Matthews H, Shinefield H et al (2004) Ten year followup of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 23(2):132-137 (Pubitemid 38222785)
20. Lee LE, Ho H, Lorber E, Fratto J, Perkins S, Cieslak PR (2008) Vaccine-era varicella epidemiology and vaccine effectiveness in a public elementary school population, 2002-2007. Pediatrics 121: e1548-e1554
21. Lopez AS, Guris D, Zimmerman L, Gladden L, Moore T, Haselow DT, Loparev VN, Schmid DS, Jumaan AO, Snow SL (2006) One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics 117:e1070-e1077 (Pubitemid 46074632)
22. Marin M, Güris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC) (2007) Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56:1-40
23. Marin M, Meissner HC, Seward JF (2008) Varicella prevention in the United States: a review of successes and challenges. Pediatrics 122:e744-e751
24. Mauldin J, Carbone K, Hsu H, Yolken R, Rubin S (1990) Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays. J Clin Microbiol 43:4847-4851
25. Miron D, Lavi I, Kitov R, Hendler A (2005) Vaccine effectiveness and severity of varicella among previously vaccinated children during outbreaks in day-care centers with low vaccination coverage. Pediatr Infect Dis J 24:233-236 (Pubitemid 40365857)
26. Nader S, Bergen R, Sharp M, Arvin AM (1995) Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 171:13-17
27. National Advisory Committee on Immunization (NACI) (2004) Update on varicella. Can Commun Dis Rep 30:1-26
28. Ngai AL, Staehle BO, Kuter BJ, Cyanovich NM, Cho I, Matthews H, Keller P, Arvin AM, Watson B, White CJ (1996) Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J 15:49-54 (Pubitemid 26029243)
29. Nguyen HQ, Jumaan AO, Seward JF (2005) Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 352:450-458 (Pubitemid 40175971)
30. Quian J, Rüttimann R, Romero C, Dall'orso P, Cerisola A, Breuer T, Greenberg M, Verstraeten T (2008) Impact of universal varicella vaccination of one year-olds in Uruguay: 1997-2005. Arch Dis Child 93:845-850
31. Rawson H, Crampin A, Noah N (2001) Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ 323:1091-1093 (Pubitemid 33063350)
32. Rozenbaum MH, van Hoek AJ, Vegter S, Postma MJ (2008) Costeffectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines 7:753-782
33. Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P (2008) Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J 27:724-730
34. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson WP, Gershon AA (2000) The postmarketing safety profile of varicella vaccine. Vaccine 19:916-923
35. Sheffer R, Segal D, Rahamani S, Dalal I, Linhart Y, Stein M, Shohat T, Somekh E (2005) Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel. Pediatr Infect Dis J 24:434-437 (Pubitemid 40664239)
36. Varis T, Vesikari T (1996) Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis 174: S330-S334 (Pubitemid 26357217)
37. Vesikari T, Baer M, Willems P (2007) Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J 26:153-158 (Pubitemid 46183366)
38. Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D, Cnaan A, Starr SE (1995) Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 20:316-319
39. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A (2005) Impact of varicella vaccination on health care utilization. JAMA 294:797-802 (Pubitemid 41175722)
40. Zhou F, Ortega-Sanchez IR, Guris D, Shefer A, Lieu T, Seward JF (2008) An economic analysis of the universal varicella vaccination program in the United States. J Infect Dis 197:S156-S164 (Pubitemid 351590165)
41. Ziebold C, von Kries R, Lang R, Weigl J, Schmitt HJ (2001) Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Pediatrics 108:E79